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Introduction
The revolution in biological knowledge in the past two
decades, with the ability to manipulate, sequence, clone
and transfect DNA, has resulted in the sequencing of multi-
ple prokaryotic and eukaryotic genomes, and has spawned
a whole new industry, the biotechnology industry — now a
major segment of the pharmaceutical industry. This has
led to the development of important new drugs, such as
cytokines, as well as monoclonal antibodies and receptor
Fc fusion proteins.
In this chapter, we will present evidence, using tumour
necrosis factor (TNF)-α as our example, that gene regula-
tion is complex and varies depending on the cell type, as
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Chapter summary
The elucidation of the signalling pathways involved in inflammatory diseases, such as rheumatoid
arthritis, could provide long sought after targets for therapeutic intervention. Gene regulation is
complex and varies depending on the cell type, as well as the signal eliciting gene activation. However,
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methods of gene delivery and the difficulties associated with each system. Adenoviruses have been
used extensively to examine the role of various cytokines and signal transduction molecules in the
pathogenesis of rheumatoid arthritis. This review will focus on the involvement of different signalling
molecules in the production of tumour necrosis factor alpha by macrophages and in rheumatoid
synovium. While the NF-κB pathway has proven to be a major mediator of tumour necrosis factor alpha
production, it is not exclusive and work evaluating the involvement of other pathways is ongoing.
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well as the signal eliciting gene activation. Analysis of
gene regulation is typically performed in transformed cell
lines with, for example, footprinting analysis and DNase
protection to evaluate which portions of DNA are ‘pro-
tected’ by transcription factors. With genes induced by
multiple signals, such as TNF-α, however, it is not clear
whether every signal operates in the same way in every
cell. Prior literature suggested they did not, since in human
T-cell lines (JURKAT), TNF-α synthesis was nuclear
factors of activated T cells (NFAT)-dependent and NF-κB-
independent, whereas in murine macrophages it was
NF-κB dependent [1]. Hence, while a useful indicator,
knowledge of the sites in the promoter for transcription
factors would not have yielded any definitive data pertain-
ing to a given circumstance.
We will also present evidence that there are new
approaches of high-efficiency gene delivery that do permit
the elucidation of gene function in physiological and
pathological circumstances. The technique we have devel-
oped employs replication-deficient adenoviruses, but other
efficient delivery systems can also be equally valuable for
defining gene function. However, their utility may depend
on the particular cell system being investigated.
The problem of gene delivery
Certain molecular techniques, while yielding new informa-
tion, have limitations. DNA transfer by transfection has low
efficiency in easily transfectable transformed cell lines (e.g.
HEK 293, COS, CHO), but almost no efficiency in normal
‘primary’ cells. Low-efficiency DNA transfection need not be
a rate-limiting step, as cells stably transfected with DNA can
be detected, sorted or cloned. However, there are problems
that cannot be overcome. One problem is that transfectable
cells from certain lineages such as macrophages, a cell type
of major importance in inflammation and chronic rheumatoid
diseases, are specialised to degrade exogenous material
(such as DNA) and consequently do not transfect. Gene
function in one cell type may not be identical to that in
another; hence, conclusions made in transfectable cell lin-
eages may not extrapolate to other nontransfectable cells.
Furthermore, transformed cell lines have enormous abnor-
malities in their genomes, with deletions, duplications and
alterations in chromosome number.
We therefore explored methods of DNA delivery to non-
transformed cells, both normal and cells from pathological
sites, that yield effective DNA transfer into >90% of cells.
This level of transfer would permit the inhibition of sig-
nalling pathways by the inserted DNA. This DNA may
encode an endogenous inhibitor (e.g. inhibitor of kappa B
alpha [IκBα], which binds NF-κB), a dominant negative
(i.e. blocks normal or ‘wild type’ product), mutation of a
kinase or transcription factor, a DNA encoding an anti-
sense mRNA, or even a DNA encoding a single-chain anti-
body variable region.
Methods of DNA delivery
Current gene delivery systems can be broadly categorised
into two main groups: nonviral (plasmid DNA, DNA-coated
gold particles, liposomes and polymer DNA complexes),
and viral vectors (adenovirus, retrovirus, adeno-associated
virus, lenti-virus and herpes virus).
Nonviral vectors
Nonviral vectors attract considerable interest as they lack
some of the risks inherent with viral vectors. Nonviral DNA
delivery is less toxic, less immunogenic, and easier to
prepare. However, DNA delivery is significantly less efficient
and gene expression only occurs over a short duration,
posing serious limitations and opportunities for the use of
these systems for long-term treatment of rheumatic and
other diseases. In addition, inflammatory responses follow-
ing in vivo delivery of DNA and lipid–DNA complexes have
been reported [2–4]. The exact mechanism is currently
unknown, but might be related to the presence of unmethy-
lated CpG motifs in plasmid DNA propagated in bacteria.
Naked or plasmid DNA
DNA can be directly administered to skeletal muscle via
an intramuscular injection of ‘naked’ plasmid DNA.
However, gene expression was restricted to cells nearest
the route of injection, and less than 1% of the plasmid
DNA was incorporated into the cells [5]. Systemic admin-
istration has been even less successful. Intravenous injec-
tion of naked plasmid DNA showed no gene expression,
even in the liver, where the highest uptake was observed
[6]. Liu et al. have more recently shown that it is possible
to achieve systemic administration of naked DNA under
hydrostatic pressure by injecting a large volume of DNA
solution via the tail vein of mice [7]. Although these experi-
ments demonstrate that it may be possible to deliver
naked DNA to cells, this is not a feasible option for explor-
ing gene function.
Gene gun
Particle-mediated (‘gene gun’) gene transfer has been
applied to various cells and tissues. Gold particles coated
with plasmid DNA are propelled at the target tissue at
pressures of 150–200 psi. The efficiency of this system
varies, with skin cells showing the greatest uptake of
10–20% [8]. This system has been used to deliver a
nucleic acid-based hepatitis B vaccine to both mice and
humans, and is presently in clinical trials [9]. The major lim-
itations are the shallow penetration of particles, associ-
ated cell damage, and the inability to deliver the DNA
systemically.
Cationic lipids and polymers
Cationic lipids, such as cationic derivatives of cholesterol
and diacylglycerol, quarternary ammonium detergents, and
lipid derivatives of polyamines condense plasmid DNA to
form particles based on the electrostatic interaction and toS217
protect it from degradation. Mahato et al. reported
clearance of liposome plasmid DNA from the circulation
within 60 min, resulting in extensive accumulation in the
lung and liver after intravenous injection in mice [6]. DNA
complex properties, such as molecular weight, particle
size, and electrical charge, are important considerations
for biodistribution of carriers after intravenous injection.
The development of carrier systems that escape unde-
sired tissue uptake and exhibit target cell-specificity is
therefore required to make this a viable in vivo system
[10]. Although this method improves the ability of DNA to
evade swift degradation, delivery to target cells is still
elusive and expression of the transgene is short lived.
Cationic polymers (amino acids) are soluble in water, are
biodegradable, are not significantly immunogenic, and
have multiple functional groups that can be chemically
modified. These cationic polymers are also more effective
at condensing DNA than cationic lipids. Among various
poly(amino acids) available, poly(glutamic acid) and
poly(lysine) have been widely used as carrier backbones.
Viral vectors
Since the evolution and survival of viruses is based on
their ability to infect cells and to replicate their genes, it is
not surprising that viral vectors have proven to be the most
efficient vehicles for DNA delivery to cells both in vitro and
in vivo. Viruses also permit greater duration of transgene
expression. This is particularly relevant when attempting to
treat chronic conditions, such as rheumatoid arthritis (RA),
osteoarthritis, cystic fibrosis, or muscular dystrophy, where
enduring transgene expression is desirable. Viral vectors
are capable of delivering exogenous cDNA to the syn-
ovium, enabling effective levels of intra-articular transgene
expression following direct injection to the joint. The
expression of certain gene products has proven to be suf-
ficient to inhibit the progression of disease in animals with
experimental arthritis, even when the virus is administered
after onset of inflammation (see later).
Adeno-associated virus
Adeno-associated virus (AAV) is a single-stranded DNA
parvovirus that causes no known pathology in humans.
AAV infection involves attachment to a variety of cell
surface receptors (heparan sulfate, integrins, and fibro-
blast growth factor receptor 1) followed by clathrin-depen-
dent or clathrin-independent internalisation [11]. Although
the wild-type AAV integrates into a specific locus (AAVS1)
on the human chromosome 19, recombinant AAV vectors
do not because they lack the rep gene. Consequently,
gene expression is transient [12]. Transgenes of up to
5 kb can be accommodated within the 4.68 kb single-
stranded DNA virus, and AAV infects a wide variety of
dividing and nondividing cells. Recombinant AAV encodes
no viral proteins, reducing its immunogenicity and capacity
to stimulate an inflammatory response.
Two different groups have recently shown that AAV
encoding IL-4 promotes long-term (up to 7 months) pro-
tection from articular cartilage destruction and ameliora-
tion of disease severity in mice with collagen-induced
arthritis (CIA) [13,14]. Additionally, intra-articular injection
of AAV encoding soluble TNF receptor I significantly
decreased synovial hyperplasia, and cartilage and bone
destruction, in TNF-α transgenic mice [15].
Herpes simplex viruses
The herpes simplex virus (HSV) offers several potential
benefits that could be useful for treating arthritic condi-
tions. More than one-half of the 152 kb genome of HSV is
not required for replication in vitro, and large genes or
multiple genes can therefore be accommodated by this
vector. HSV also develops latency in certain cell types,
where the viral genome persists for the life of the host cell
without integrating into the genome and without altering
host cell metabolism. Although most of the immediate-
early genes are inactivated, HSV vectors still express low
levels of some viral proteins, resulting in an inflammatory
response [16]. Administration of HSV-derived vectors as
DNA–liposome complexes improves in vivo transduction
efficiency by evading the host anti-HSV immunity during
systemic administration [15,17]. The delivery of a HSV
vector encoding human interleukin-1 receptor antagonist
(IL-1Ra) to the joints of rabbits with experimental arthritis
has been shown to ameliorate inflammation [18].
Retroviruses
Retroviruses derived from the Moloney murine leukaemia
virus have been used extensively in the laboratory and in
clinical trials. They are able to incorporate 8–10 kb exoge-
nous DNA, and they contain no native viral coding
sequences. Retroviruses integrate their genome into that
of the host cell, resulting in sustained transgene expres-
sion. This feature of retroviruses also presents a potential
hazard beccause insertional mutagenesis could occur fol-
lowing random integration of the provirus into the host
genome. This vector is currently used to treat the rare
lethal immune disorder, severe combined immunodefi-
ciency-X1, in children [19]. Successful application of
these vectors for the study of gene function and gene
therapy, however, has often proven difficult because they
are unable to transduce quiescent cells [20].
Immortalised embryonic DBA/1 fibroblasts, infected with a
retrovirus expressing murine IFN-β ex vivo and subsequently
implanted intraperitoneally into mice immunised with bovine
type II collagen, were able to prevent the onset of arthritis or
to ameliorate existing disease [21]. Recent work by Croxford
et al. has shown that fibroblasts, transduced with retroviral
vectors expressing IL-10, could inhibit experimental allergic
encephalomyelitis, which is a central nervous system autoim-
mune disease mediated by the action of CD4+ T cells,
macrophages, and proinflammatory cytokines [22].
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Transgene expression, similar to that observed with ex
vivo administration, has been achieved using direct admin-
istration of high-titre retroviruses into the arthritic joint
[23,24]. However, high-titre preparations of Moloney
murine leukaemia virus-based vectors have been difficult
to generate routinely, and this has limited studies involving
direct retroviral-mediated gene delivery.
The only clinical trial on gene therapy of RA involving nine
patients was performed in the USA using a retroviral
vector containing the cDNA for IL-1Ra. Synovial tissue
was removed by joint surgery, and cells were expanded
and infected in vitro before being re-introduced into the
joint space. Synovial tissue was removed 1 week later by
joint arthroplasty for analysis, showing evidence of IL-1Ra
expression at both mRNA and protein levels. This study of
local ex vivo retroviral gene therapy of RA demonstrated
that safe and effective transgene expression could be
achieved [25].
Adenoviruses
The remainder of this review will focus on the development
and use of adenoviruses in vitro and in vivo. Replication-
deficient adenoviruses are one of the most widely used
systems for preclinical experimentation owing to their effi-
ciency and technically straightforward methods for gener-
ating high-titre recombinant adenoviruses [26,27].
Adenoviral particles are ~70–100 nm non-enveloped
icosahedrons that contain a ~35 kb double-stranded DNA
genome and can infect a wide range of cell types.
Adenoviruses are endocytosed by attachment of their fibre
protein to the coxsackievirus and adenovirus receptor
(CAR) [28]. This process is facilitated by interactions
between the penton base protein and integrins on the cell
surface. This latter interaction induces release of the fibre
protein and initiates internalisation of bound virions into
early endosomes via clathrin-coated pits. After internalisa-
tion and endosomal escape, adenovirus particles undergo
a stepwise disassembly programme and, finally, delivery of
viral DNA to the nucleus. This viral DNA exists as extra-
chromosomal DNA, resulting in transient gene expression
(Fig. 1). The first generation of adenoviruses commonly
used for preclinical research are devoid of the E1, E3
regions of the viral genome (Fig. 2). This prevents virus
replication while providing the space required to insert
your gene of interest. The ability of adenoviruses to infect
nearly 100% of cells, quiescent and dividing, makes it an
extremely useful vehicle for gene delivery.
Heterogeneity of gene regulation: dependent
on cell type and signals
Adenoviruses have been used to analyse macrophages
(monocytes differentiated for 2 days with macrophage
colony stimulating factor) stimulated to produce TNF-α by
a range of signals. Lipopolysaccharide (LPS), UV light,
and phorbol 12-myristate 13-acetate (PMA) were shown
to be NF-κB dependent, while zymosan and anti-CD45
were NF-κB independent, demonstrating that within a
single cell type the stimulus determined the signalling
pathway [29]. Again there were differences in T-cell-
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Figure 1
Schematic representation of the adenoviral attachment and internalisation. CAR, Coxsackievirus and adenovirus receptor.S219
dependent stimulation of macrophage TNF-α production,
with T-cell receptor-activated T cells showing NF-κB-inde-
pendent TNF-α production whereas bystander cytokine-
activated T cells were driving NF-κB-dependent TNF-α
[30]. The production of TNF-α in antigen-activated T cells
was different from that in macrophages because in cell
lines it appeared to be NF-κB independent.
A variety of cytokines and cytokine inhibitors produced by
macrophages have been tested for their dependence on
NF-κB using the IκBα adenovirus. It appears that NF-κB
regulates essentially all proinflammatory cytokines,
although not with every stimulus. Second, NF-κB does not
regulate anti-inflammatory cytokines, such as IL-10, IL-11
or IL-1Ra, but has moderate effects on shedding of
soluble TNF receptor. Third, there were differences within
a single study (e.g. LPS) in the degree to which different
proinflammatory cytokines were NF-κB dependent. IL-6
was ~80% inhibited, whereas TNF and IL-1 were 60%
inhibited and IL-8 was only inhibited by 30–40%. The
results varied with different stimuli; for example, with
TNF-α stimulation, IL-8 is >60% NF-κB dependent. The
reasons for these differences are not known. However, it
is possible that other transcription factors are used for
IL-1 and IL-8 production in response to LPS [31].
Work by Pope et al. has shown that PMA-treated
macrophages, infected with a dominant negative CCAAT/
enhancer binding protein beta (C/EBPβ) adenovirus,
produce 60% less TNF-α in response to LPS. Furthermore,
dominant negative versions of both C/EBPβ and c-Jun, but
not NF-κB p65, suppressed PMA-induced TNF-α secre-
tion, demonstrating that C/EBPβ and c-Jun contribute to
TNF-α regulation in normal macrophages [32].
The importance of using the appropriate model for study-
ing gene regulation, and thereby identify potential targets
for therapy, has been aptly demonstrated by studies on
the NF-κB-inducing kinase (NIK). This enzyme was identi-
fied as kinase for IKK1/α, a part of the IκB kinase (IKK)
signalosome. Several studies on NIK have shown evi-
dence that NIK acts as a gateway for multiple activators of
NF-κB, including the key inflammatory factors, TNF-α, IL-1
and LPS. However, these studies have been exclusively
performed in transformed cell lines [33–35]. We con-
firmed these results in cell lines using an adenovirus
encoding a dominant negative version of NIK. However,
introduction of the same construct into primary human
cells of fibroblast, myeloid or endothelial lineage showed
no role for NIK in TNF-α, LPS or IL-1 signalling (Figs 3 and
4) [36]. Rather, the role of NIK was restricted to NF-κB
induction by activation of the lymphotoxin beta receptor
(LTβR) (Fig. 4) [36]. This supported studies in cells from
mice defective in NIK expression or function that showed
that NIK function was restricted to LTβR signalling [37].
Together, these data highlight the diversity inherent in sig-
nalling pathways and the potent effect that transformation
has on cell function.
Use of adenoviruses for analysis of RA and
its models
In vitro analysis on synovial tissue
As the pathology of RA is concentrated in the synovium,
analysis of this tissue can provide major insights into its
pathogenesis. A key question was therefore whether
adenoviruses could effectively infect human synovial cells
in vitro and, if so, whether all cell types infect equally. It
was found that >90% of synovial cells were infected at a
multiplicity of virus of 40:1 using a β-galactosidase
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Figure 2
Schematic diagram of the adenoviral genome. In the first generation of adenoviral vectors, the E1A, E1B and E3 regions have been deleted to
allow for insertion of your gene of interest. CMV, cytomegalovirus.S220
reporter virus (Fig. 5) [31]. Furthermore, it was established
by flow cytometry that all subpopulations of cells were
infected; macrophages, fibroblasts and also >80% of T
cells. The surprising result indicated that cells from patho-
logical sites are easier to infect than resting cells, probably
due to their prior exposure to cytokines. This observation
enabled us, in parallel with others, to evaluate the role of
various signalling molecules in rheumatoid synovium.
With the IκBα adenovirus, we showed that multiple pro-
inflammatory cytokines are downregulated: TNF-α by
70%, IL-6 by 80%, and IL-1 by ~50% (as shown in Fig.5).
In contrast, anti-inflammatory mediators were not affected.
These results parallel prior studies with macrophages. The
variable degree of inhibition indicates that, while NF-κB is
of major importance, other important transcription factors
are involved, especially for IL-1 and IL-8. The blockage of
NF-κB resulted in the downregulation of degradative
enzymes, with matrix metalloproteinases MMP-1 and
MMP-3 markedly reduced. In contrast, the tissue inhibitor
of matrix metalloproteinases, TIMP-1, was not downregu-
lated [38]. Taken together, the local effects of NF-κB
blockade would be very beneficial for RA. Much work has
been carried out to define the inducers of NF-κB and to
subsequently generate inhibitors (e.g. inhibitors of IKK2).
Adenoviral-mediated gene delivery of a non-degradable
IκBα, or dominant negative versions of C/EBPβ or c-Jun,
has been examined to determine the contribution of each
transcription factor to IL-6 and IL-8 expression by RA
fibroblast-like synoviocytes. Inhibition of NF-κB activation
significantly reduced the spontaneous and IL-1β-induced
secretion of IL-6 and IL-8. Conversely, inhibition of
C/EBPβ and c-Jun/AP-1 had little or no effect on the pro-
duction of either IL-6 or IL-8 [39].
The p38 mitogen-activated protein kinase (MAPK) is an
important regulator of cytokine production, including
TNF-α. While drugs blocking p38 MAPK (e.g. SB203570)
were effective at blocking LPS-induced TNF-α, they were
less effective at blocking spontaneous synovial TNF-α pro-
duction. Specific p38 MAPK inhibitors, encoded in aden-
oviral constructs, were constructed to examine their
effectiveness in rheumatoid synovial cultures. It was found
that up to 80% of spontaneously produced TNF-α was
inhibited (Ciesielski et al., manuscript in preparation).
In vivo effects on animal models of arthritis
Adenoviral vectors have been extensively used in preclini-
cal studies on gene therapy of RA using a number of
animal models of arthritis. Two main strategies have been
employed: systemic delivery, whereby vectors are injected
intravenously; and local delivery, whereby genes are trans-
ferred to the joint, either via direct injection into the joint (in
vivo), or by infecting autologous synovial cells in vitro and
transferring the transformed cells into the joint (ex vivo).
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Figure 3
(a) Nuclear factor-kappa B (NF-κB)-dependent gene induction in HeLa
57A cells is NF-κB-inducing kinase (NIK) dependent. HeLa 57A cells
were infected with Adv.GFP, Adv.IκBα, or Adv.NIK-kd as indicated
(moi 50) and left for 24 hours to allow transgene expression. Cells
were stimulated for 4 hours with vehicle (no shading), with 25 ng/ml
tumor necrosis factor (TNF)-α (solid shading), or with 10 ng/ml IL-1α
(hashed shading). Cell lysates were then prepared and luciferase
activities assessed (n = 3, ± SEM). (b, c) NIK is not required for
lipopolysaccharide (LPS)-induced or TNF-α-induced cytokine
expression in primary human macrophages. Primary human
macrophage colony stimulating factor-differentiated macrophages
were infected with Adv.GFP or Adv.NIK-kd as indicated (moi 100) and
left for 24 hours to allow transgene expression. Cells were then
stimulated for a further 24 hours with vehicle (no shading), with
10 ng/ml LPS (hashed shading), or with 25 ng/ml TNF-α (solid
shading). Cell supernatants were collected and secreted IL-6 and
TNF-α levels were determined by enzyme-linked immunopsorbent
assay (n = 3, ± SEM).S221
Modulation and suppression of experimental arthritis has
been achieved by the systemic gene delivery of a variety of
anti-inflammatory and immunosuppressive proteins. Sus-
tained amelioration of murine CIA was demonstrated in
our studies. An adenovirus encoding IL-10, when injected
intravenously, produced elevated serum levels of murine
IL-10 that reduced cell-mediated immune reactivity and
IFN-γ production without affecting antibody responses.
Interestingly, IL-10 was also able to suppress adenovirus-
induced hepatic inflammation, a limitation of the first-
generation adenoviral vectors [40].
Systemic delivery of an adenovirus encoding the cytotoxic
T lymphocyte antigen CTLA4-Ig, an inhibitor of the CD28/
CD80 and CD86 interaction between T cells and antigen-
presenting cells, has also been investigated by our group.
This treatment was similarly very effective, even if adminis-
tered after onset of arthritis, being just as effective as
protein delivery in optimal concentrations [41]. With the
systemic injection of an adenovirus encoding an immuno-
genic protein, strikingly different results were obtained.
The human p55 TNF receptor coupled to a mouse IgG Fc
fusion protein gene, inserted into an adenoviral vector and
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Figure 4
Nuclear factor-kappa B (NF-κB)-inducing kinase (NIK) is dispensable for tumour necrosis factor (TNF) receptor but is essential for lymphotoxin
beta-receptor (LTβR)-induced NF-κB activation in primary human skin fibroblasts. Primary human skin fibroblasts were infected with Adv.GFP,
Adv.NIK-kd, Adv.IKK2-kd or Adv.IκBα (moi 50) and left for 24 hours to allow transgene expression. (a) Cells were stimulated with vehicle (control),
with 25 ng/ml TNF-α or with 50 ng/ml LTα1β2 for 30 min prior to the preparation of cytosolic and nuclear extracts. Cytosolic IκBα levels were
determined by western blotting (upper panel). Nuclear NF-κB DNA-binding activities were determined by electrophoretic mobility shift assay
(EMSA) (lower panel). (b) Cells were stimulated with vehicle (control), with 25 ng/ml TNF-α or with 50 ng/ml LTα1β2 for 24 hours, and secreted
IL-6 levels were determined by enzyme-linked immunosorbent assay (n = 3, ± SEM).S222
injected systemically in arthritic mice, induced elevated
serum levels of the fusion protein and ameliorated CIA for
up to 7–10 days. Then, a dramatic inflammatory rebound
was observed and treated mice appeared sicker than con-
trols. These findings confirm prior reports on the role of
host immune reactions elicited more towards the product
of gene transduction than to the virus itself.
The group of Robbins and Evans has reported successful
treatment of murine CIA with an adenovirus encoding IL-4
[42]. This treatment was also effective in the rat model of
adjuvant arthritis after disease onset, and decreased levels of
TNF-α, IL-1β, macrophage inflammatory protein-2, and
CCL5 (the chemokine ligand for CCR5) were reported [43].
A local intra-articular approach has also been investigated
using adenoviral vectors. As mutations in the tumour sup-
pressor protein p53 are observed in synovial cells from
some RA patients, overexpression of p53 by adenoviral
gene transfer in synovial cell cultures in vitro, and in syn-
ovial tissue in vivo, has been achieved in a rabbit model of
arthritis, and resulted in significant apoptosis. In addition,
the intra-articular injection of p53 adenovirus determined a
rapid induction of synovial apoptosis in the rabbit knee
joint without affecting cartilage metabolism [44].
Makorov et al. have shown in a rat model of arthritis that
local injection of a retrovirus expressing a mutant, non-
degradable IκBα, induces improvements in joint disease
[45]. This work is supported by experiments using another
member of the NF-κB pathway; inhibitor of NF-κB kinase
beta (IKKβ). Intra-articular injection of adenovirus encod-
ing IKKβ-wt into the joints of normal rats caused signifi-
cant paw swelling and histologic evidence of synovial
inflammation. Increased IKK activity was detectable in the
IKKβ-wt-injected ankle joints, coincident with enhanced
NF-κB DNA binding activity, while a dominant negative
version of IKKβ significantly ameliorated disease severity
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Figure 5
(a) Efficiency of infection of rheumatoid arthritis (RA) joint cell cultures. RA joint tissues were obtained from the synovium from patients with RA
undergoing surgery. Cells were infected with Advβgal (moi 40) for 48 hours prior to analysis of the cells for βgal expression by fluorescence
activated cell sorting (FACS). (B) Effect of IκBα transgene expression on cytokine expression in RA joint cell cultures. RA joint cells were infected
with AdvIκBα or AdvO (moi 40). Culture supernatants were harvested after 48 hours and analysed for the expression of various cytokines by
enzyme-linked immunosorbent assay. Data are representative of samples from at least five patients. IL-1RA, interleukin-1 receptor antagonist; TNF,
tumour necrosis factor; sTNFR, soluble TNF receptor.S223
of adjuvant arthritis, and determined a significant decrease
in NF-κB DNA expression [46].
The work described here regarding animal models of
arthritis has been supplemented by a number of studies
using retroviruses that were used to infect cell lines in
vitro and then injected systemically in vivo [47].
Future prospects
The working draft covering 97% of the human genome
was completed in June 2000. It is expected that the ‘fin-
ished’ sequence of greater than 99.99% accuracy will be
completed within the next year. Analysis of the current
sequence shows 38,000 predicted genes and many of
these have no known function. Expectations within the
pharmaceutical industry have been high that this knowl-
edge will be transformed into therapeutic targets and new
drugs. These expectations have so far not been met
because crucial roadblocks remain in the elucidation of
target genes for drug development. Expectations have
been raised about the possibility of performing drug devel-
opment ‘in silico’ using genetic information, but suc-
cesses from this approach remain to be achieved.
The ability to explore gene function both in vitro and in
vivo is paramount to the elucidation of gene regulation and
potential targets for therapeutic intervention. While sub-
stantial work has been undertaken to determine the sig-
nalling pathways controlling TNF-α production and other
inflammatory mediators, the roles of a multitude of
cytokines, cytokine receptors, kinases and phosphatases
remain to be explored.
Research into developing high-efficiency vectors for trans-
gene delivery is a continually evolving field of research.
Current research into developing cationic lipids/polymers
for cell-specific delivery via receptor-mediated endocyto-
sis, such as galactose, mannose, lactose, transferrin, epi-
dermal growth factor, asialoglycoprotein and antibodies,
may provide valuable advances allowing the targeting of
specific cell populations [10]. Combining advances in
DNA delivery via directed cationic lipids and polymers,
and improved adenoviral or other viral vectors, looks to be
a promising approach to evade clearance and to deliver
stable gene expression to specific cells [48,49].
Although adenoviruses have proved valuable tools for pre-
clinical research, the first generation of E1, E3 deleted
vectors still contains native viral-coding sequences
expressed at low levels, resulting in inflammatory
responses (Fig. 2) [50]. Furthermore, expression of these
viral proteins leads to the clearance of transduced cells,
limiting transgene expression [51]. Recently described
helper-dependent, or gutless, adenoviral vectors may over-
come many of these problems. These adenoviruses do not
encode any viral coding sequences and have shown an
excellent expression profile in a variety of animal models,
as well as reduced toxicity after local or systemic delivery
[52]. Expression of the transgene can be detected for
many months and the gutted adenoviruses do not elicit an
immune response in animals previously immunised against
the same adenovirus serotype [53].
Concluding remarks
There has been much progress in the development of
methods of gene transfer into normal cells and cells from
pathological sites. These techniques can be used to test
the function of genes, allegedly known or unknown both in
vivo and in vitro. These approaches can be used to eluci-
date important pathways, and to help confirm or define
therapeutic targets.
Glossary of terms
AAV = adeno-associated virus; C/EBPβ = CCAAT/
enhancer binding protein beta; HSV = herpes simplex virus;
IKK = IκB kinase; IKKβ = inhibitor of NF-κB kinase beta;
IL-1Ra = interleukin-1 receptor antagonist; LTβR = lympho-
toxin beta-receptor; NIK = NF-κB-inducing kinase.
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